FLGT News and Press, Fulgent Genetics Inc. From 07/28/20

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

Original post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Today's headlines need not be tomorrow's storyline ." - Craig D. Lounsbrough Today, we look at a name that fell back into ' Busted IPO' territory at the end of COVID-19 meltdown. The shares have popped back sharply since then, like so many equities over the past several months. Should in...

TEMPLE CITY, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. Th...

Carver Bancorp (NASDAQ: CARV ) +232% . More news on: Carver Bancorp, Inc., Urban One, Inc., Energous Corporation, Stocks on the move, , Read more ...

Fulgent Genetics (NASDAQ: FLGT ) is up 10% postmarket after launching its at-home testing solution for COVID-19. More news on: Fulgent Genetics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers:  INWK +46.6% . FLGT +9.3% . GRPN +4.7% . STWD +4.6% . MG +4.2% . More news on: InnerWorkings, Inc., Fulgent Genetics, Inc., Groupon, Inc., Stocks on the move, , Read more ...

TEMPLE CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing solutions, today announced that it has launched an at-home testing solution for the Cor...

Fulgent Genetics (FLGT) has rapidly developed a couple of tests for COVID-19, which is at least in part substituting the pandemic-related decline in its core business, but we think the latter is temporary, as were the incurred costs for developing the COVID-19 tests. As demand for the compan...

Sorrento Therapeutics (NASDAQ: SRNE ) +36%  in reaction to  reports  that it has discovered an antibody, dubbed STI-1499, that, it says, can provide 100% inhibition of COVID-19. More news on: Sorrento Therapeutics, Inc., Moderna, Inc., Fulgent Genetics, Inc., Stocks on the ...